Laboratory Corporation of America Holdings (LH) Shares Bought by Sentry Investment Management LLC

Sentry Investment Management LLC grew its stake in Laboratory Corporation of America Holdings (NYSE:LH) by 1.0% during the 2nd quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 7,756 shares of the medical research company’s stock after purchasing an additional 78 shares during the period. Sentry Investment Management LLC’s holdings in Laboratory Corporation of America Holdings were worth $1,196,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors also recently bought and sold shares of LH. Acrospire Investment Management LLC grew its position in Laboratory Corporation of America Holdings by 16.5% in the 2nd quarter. Acrospire Investment Management LLC now owns 705 shares of the medical research company’s stock worth $109,000 after purchasing an additional 100 shares during the last quarter. Sun Life Financial INC grew its position in Laboratory Corporation of America Holdings by 9,200.0% in the 2nd quarter. Sun Life Financial INC now owns 744 shares of the medical research company’s stock worth $115,000 after purchasing an additional 736 shares during the last quarter. Parallel Advisors LLC grew its position in Laboratory Corporation of America Holdings by 377.7% in the 1st quarter. Parallel Advisors LLC now owns 1,261 shares of the medical research company’s stock worth $177,000 after purchasing an additional 997 shares during the last quarter. IFP Advisors Inc grew its position in Laboratory Corporation of America Holdings by 83.9% in the 2nd quarter. IFP Advisors Inc now owns 1,146 shares of the medical research company’s stock worth $177,000 after purchasing an additional 523 shares during the last quarter. Finally, Hourglass Capital LLC acquired a new stake in Laboratory Corporation of America Holdings in the 2nd quarter worth $200,000. Institutional investors own 92.97% of the company’s stock.

Several analysts have issued reports on the stock. Robert W. Baird restated a “hold” rating and issued a $166.00 price target on shares of Laboratory Corporation of America Holdings in a research report on Tuesday. SunTrust Banks, Inc. restated a “buy” rating and issued a $190.00 price target on shares of Laboratory Corporation of America Holdings in a research report on Thursday, October 12th. Wells Fargo & Company initiated coverage on shares of Laboratory Corporation of America Holdings in a research report on Thursday, October 12th. They issued an “outperform” rating and a $175.00 price target on the stock. Zacks Investment Research raised shares of Laboratory Corporation of America Holdings from a “hold” rating to a “buy” rating and set a $170.00 price objective for the company in a report on Tuesday, October 10th. Finally, KeyCorp reaffirmed a “hold” rating on shares of Laboratory Corporation of America Holdings in a report on Tuesday, September 26th. Six analysts have rated the stock with a hold rating, nine have given a buy rating and one has assigned a strong buy rating to the company’s stock. The stock has an average rating of “Buy” and a consensus target price of $170.31.

Laboratory Corporation of America Holdings (NYSE LH) traded up 1.86% during trading on Thursday, hitting $150.75. 191,790 shares of the stock were exchanged. The stock has a market capitalization of $15.35 billion, a price-to-earnings ratio of 21.11 and a beta of 0.92. The firm has a 50-day moving average of $152.98 and a 200-day moving average of $149.02. Laboratory Corporation of America Holdings has a 52 week low of $119.51 and a 52 week high of $164.22.

Laboratory Corporation of America Holdings (NYSE:LH) last released its quarterly earnings results on Wednesday, July 26th. The medical research company reported $2.47 EPS for the quarter, beating the Thomson Reuters’ consensus estimate of $2.40 by $0.07. Laboratory Corporation of America Holdings had a net margin of 7.57% and a return on equity of 16.85%. The business had revenue of $2.50 billion for the quarter, compared to the consensus estimate of $2.47 billion. During the same period in the prior year, the company posted $2.36 earnings per share. Laboratory Corporation of America Holdings’s revenue was up 4.9% compared to the same quarter last year. Equities research analysts anticipate that Laboratory Corporation of America Holdings will post $9.51 earnings per share for the current fiscal year.

In related news, CFO Glenn A. Eisenberg sold 5,968 shares of the company’s stock in a transaction dated Tuesday, August 1st. The shares were sold at an average price of $159.46, for a total transaction of $951,657.28. Following the completion of the sale, the chief financial officer now owns 18,122 shares of the company’s stock, valued at $2,889,734.12. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, CEO David P. King sold 44,687 shares of the company’s stock in a transaction dated Wednesday, September 6th. The stock was sold at an average price of $156.86, for a total transaction of $7,009,602.82. Following the sale, the chief executive officer now directly owns 258,753 shares of the company’s stock, valued at approximately $40,587,995.58. The disclosure for this sale can be found here. Insiders sold 222,968 shares of company stock worth $34,980,922 over the last 90 days. 0.90% of the stock is currently owned by corporate insiders.

TRADEMARK VIOLATION NOTICE: “Laboratory Corporation of America Holdings (LH) Shares Bought by Sentry Investment Management LLC” was first posted by Sports Perspectives and is owned by of Sports Perspectives. If you are reading this report on another site, it was stolen and reposted in violation of US & international copyright law. The legal version of this report can be accessed at https://sportsperspectives.com/2017/10/19/laboratory-corporation-of-america-holdings-lh-shares-bought-by-sentry-investment-management-llc.html.

Laboratory Corporation of America Holdings Company Profile

Laboratory Corporation of America Holdings is a life sciences company that is integrated in guiding patient care, providing clinical laboratory and end-to-end drug development services. The Company operates as a healthcare diagnostics company. The Company operates through two segments: LabCorp Diagnostics (LCD) and Covance Drug Development (CDD).

Institutional Ownership by Quarter for Laboratory Corporation of America Holdings (NYSE:LH)

Receive News & Ratings for Laboratory Corporation of America Holdings Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Laboratory Corporation of America Holdings and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply